



## Marketing Approval of Tegoprazan in Malaysia

Nagoya, Japan, September 26, 2024 – RaQualia Pharma Inc. (headquartered in Nagoya; President & CEO: Hirobumi Takeuchi, “RaQualia”) announced today that one of its licensees, HK inno.N Corporation (headquarters: Osong, South Korea; “HK inno.N”) has announced that its business partner, Pharmaniaga Logistics Sdn Bhd (Headquarters: Shah Alam, Malaysia, “Pharmaniaga”), has received marketing approval from the National Pharmaceutical Regulatory Agency (NPRA) for the gastric acid secretion inhibitor tegoprazan (“tegoprazan”).

Tegoprazan is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. P-CABs have a different mechanism of action from proton pump inhibitors (PPIs), the first-line therapy for gastroesophageal reflux disease, and suppress gastric acid secretion more rapidly and persistently than PPIs. RaQualia and HK inno.N entered into an exclusive license agreement for developing, marketing, and manufacturing tegoprazan with sublicensing rights. HK inno.N and its business partners worldwide have been conducting business activities for tegoprazan.

Currently, tegoprazan products are marketed in nine countries, including South Korea, Mongolia, China, the Philippines, Indonesia, Singapore, Mexico, Peru, and Chile, and preparations for launch, approval reviews and clinical trials are underway in 37 countries, including the United States.

In Malaysia, in 2021, HK inno.N entered into an agreement for finished product supply with Pharmaniaga, and since then, Pharmaniaga has been working to obtain marketing approval. Approved indications include erosive gastroesophageal reflux disease, non-erosive gastroesophageal reflux disease, gastric ulcer, and *Helicobacter pylori* eradication. The brand name in the local market is K-CAB<sup>®</sup>, and Pharmaniaga expects the product to launch in the first half of 2025. The market size for peptic ulcer drugs in Southeast Asia is \$520 million, and further growth is expected. Tegoprazan is already marketed in the Philippines, Singapore, and Indonesia, as well as Malaysia, where approval has been now obtained, and is also in the process of regulatory review for approval in Thailand and Vietnam, steadily expanding its foothold in the top six countries in terms of economic scale in Southeast Asia.

Under the license agreement with HK inno.N, RaQualia has the right to receive a portion of the revenues earned by HK inno.N from sublicensees. Although RaQualia will receive no lump-sum payment due to this regulatory approval, RaQualia believes expanding the number of countries where tegoprazan is marketed will contribute to the improvement of our business revenue and corporate value in the medium to long term. RaQualia will continue to strengthen its partnership with HK inno.N, providing continuous support for the development and sublicensing to expand the options for gastric acid-related diseases, thereby making further contributions to improving patients' quality of life.

###

**RaQualia Pharma, Inc. Media Contact:**

RaQualia Pharma, Inc.

8F Meieki Southside Square, 1-21-19 Meieki Minami Nakamura-ku, Nagoya 450-0003, Japan

Tel: +81-446-6100

Email: [ask@raqualia.com](mailto:ask@raqualia.com)